Antibe Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.04.24	Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act (Businesswire)
09.04.24	Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act (Businesswire)
01.04.24	Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance (Businesswire)
20.03.24	Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting (Businesswire)
07.03.24	Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting (Businesswire)
04.03.24	Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma (Businesswire)
14.02.24	Antibe Reports Q3 2024 Interim Financial and Operating Results (Businesswire)
01.02.24	Antibe Extends Early Warrant Exercise Incentive Program (Businesswire)
29.12.23	Antibe Announces Early Warrant Exercise Incentive Program (Businesswire)
12.12.23	Antibe Therapeutics Announces Amendment to Warrant Terms (Businesswire)
13.11.23	Antibe Reports Q2 2024 Interim Financial and Operating Results (Businesswire)
09.11.23	Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation (Businesswire)
01.11.23	Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation (Businesswire)
18.10.23	Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation (Businesswire)
28.09.23	Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul (Businesswire)
08.09.23	Antibe Announces Results of 2023 Annual Meeting (Businesswire)
14.08.23	Antibe Reports Q1 2024 Interim Financial and Operating Results (Businesswire)
29.06.23	Antibe Reports 2023 Year-End Results and Business Highlights (Businesswire)
25.04.23	Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit (Businesswire)
18.04.23	Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
11.04.23	Antibe Provides April 2023 Corporate Update (Businesswire)
15.02.23	Antibe Reports Q3 2023 Interim Financial and Operating Results (Businesswire)
15.11.22	Antibe Reports Q2 2023 Interim Financial and Operating Results (Businesswire)
02.11.22	Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary (Businesswire)
12.10.22	Antibe Provides Development Update for Otenaproxesul (Businesswire)
09.09.22	Antibe Announces Results of 2022 Annual Meeting (Businesswire)
06.09.22	Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022 (Businesswire)
15.08.22	Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results (Businesswire)
30.06.22	Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights (Businesswire)
15.06.22	Antibe Therapeutics Announces Amendment to Warrant Terms (Businesswire)
25.05.22	Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs (Businesswire)
02.05.22	Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary (Businesswire)
25.04.22	Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
14.02.22	Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results (Businesswire)
28.06.21	Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights (Businesswire)
25.06.21	Antibe Therapeutics Collaborates With Dalriada Drug Discovery to Accelerate Pipeline Expansion (Businesswire)
07.05.21	Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership (Businesswire)
29.03.21	Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain (Businesswire)
07.01.21	Antibe Therapeutics Strengthens Partnering Advisory Team With Appointment of Don Haut (Businesswire)
30.11.20	Antibe Therapeutics Announces TSX Approval and Effective Date of Share Consolidation (Businesswire)
13.11.20	Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results (Businesswire)
10.11.20	Antibe Therapeutics Receives Final Approval to Graduate to the Toronto Stock Exchange (Businesswire)
30.10.20	Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange (Businesswire)
15.09.20	Antibe Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Businesswire)
31.08.20	Antibe Therapeutics to Present at Upcoming Conferences (Businesswire)
25.08.20	Antibe Therapeutics Reports Q1 2021 Interim Financial and Operating Results (Businesswire)
20.08.20	Antibe Therapeutics Announces Results of Annual and Special Meeting (Businesswire)
04.08.20	Antibe Therapeutics Provides Corporate Update (Businesswire)
02.06.20	Antibe Therapeutics to Host Conference Call to Discuss Positive Results of Phase 2B Dose-Ranging, Efficacy Study for ATB-346 (Businesswire)
01.06.20	Antibe Therapeutics Announces Positive Top-Line Data From Phase 2B Dose-Ranging, Efficacy Study For ATB-346 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	79.68	2.28 %	K V
CieFinRichemont	140.80	1.70 %	K V
Part Grp Hldg	1’292.00	0.86 %	K V
Roche Hldg G	267.10	0.83 %	K V
Alcon	76.66	0.82 %	K V
Geberit	494.40	0.00 %	K V
Swiss Re	131.10	0.00 %	K V
Sika	217.30	-0.05 %	K V
UBS Group	29.20	-0.34 %	K V
Givaudan	3’852.00	-0.85 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Antibe Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten